![Warwick Tong](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 236 597 $ in data 30/06/2026
Warwick Tong is currently Chairman at Biomedical Research Australia.
Other current roles include Independent Non-Executive Director at Amplia Therapeutics Ltd. starting in 2026, Director at Amplia Therapeutics Uk Ltd., Director at ACULEUS THERAPEUTICS PTY LTD, Director at Pacalis Therapeutics Pty Ltd., Member-Governance Board at Arc Centre For Excellence In Convergent Bio-Nano Science & Tec, and Member at Maurice Wilkins Centre.
Former positions include Chief Executive Officer & Director at Oncology One Pty Ltd. from 2011 to 2018, Chairman at CTxONE from 2018 to 2020, Chairman at Biomedical Research Victoria from 2018 to 2019, Medical Director at GlaxoSmithKline NZ Ltd. from 1993 to 1997, Medical Director at Glaxo Wellcome Manufacturing Pte Ltd., Senior Vice President-Development at Surface Logix LLC from 2010 to 2012, and Vice President-World Wide Development at GSK Plc.
Education includes graduation from Victoria University of Wellington.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 06/09/2025 | 2.355.140 ( 0,46% ) | 236 597 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| AMPLIA THERAPEUTICS LIMITED | Direttore/Membro del Consiglio | 30/06/2026 |
Biomedical Research Australia | Presidente | - |
Arc Centre For Excellence In Convergent Bio-Nano Science & Tec | Direttore/Membro del Consiglio | - |
Amplia Therapeutics Uk Ltd. | Direttore/Membro del Consiglio | - |
Maurice Wilkins Centre | Corporate Officer/Principal | - |
| Società | Posizione | Fine |
|---|---|---|
CTxONE | Amministratore Delegato | - |
Biomedical Research Victoria | Presidente | 01/12/2019 |
Oncology One Pty Ltd.
 Oncology One Pty Ltd. BiotechnologyHealth Technology Develops novel oncology drug and clinical diseases for cancer | Amministratore Delegato | 30/04/2018 |
Surface Logix LLC
 Surface Logix LLC Pharmaceuticals: MajorHealth Technology Manufactures molecular drugs | Corporate Officer/Principal | 03/10/2012 |
| ░░░░░░░░░░░░░░░ ░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 13 |
|---|---|
Surface Logix LLC
Surface Logix LLC Pharmaceuticals: MajorHealth Technology Manufactures molecular drugs | Health Technology |
Oncology One Pty Ltd.
Oncology One Pty Ltd. BiotechnologyHealth Technology Develops novel oncology drug and clinical diseases for cancer | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Victoria University of Wellington
 Victoria University of Wellington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithkline NZ Ltd.
 GlaxoSmithkline NZ Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Glaxo Wellcome Manufacturing Pte Ltd.
 Glaxo Wellcome Manufacturing Pte Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Amplia Therapeutics Ltd.
 Amplia Therapeutics Ltd. BiotechnologyHealth Technology Develops drug candidates for oncology and chronic fibrosis | Health Technology |
CTxONE | |
Biomedical Research Australia | |
Arc Centre For Excellence In Convergent Bio-Nano Science & Tec | |
Maurice Wilkins Centre | |
Biomedical Research Victoria | |
Amplia Therapeutics Uk Ltd. |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
